CDK4/6 inhibitors in lung cancer: current practice and future directions

Shuoshuo Lv; Jie Yang; Jiayuh Lin; Xiaoying Huang; Chengguang Zhao; Lehe Yang

doi:10.1183/16000617.0145-2023

journal article Open Access Jan 31, 2024

CDK4/6 inhibitors in lung cancer: current practice and future directions

Shuoshuo Lv Jie Yang

Jiayuh Lin Xiaoying Huang

Chengguang Zhao

Lehe Yang

European Respiratory Review Vol. 33 No. 171 pp. 230145 · European Respiratory Society (ERS)

View at Publisher Save 10.1183/16000617.0145-2023

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide, and ∼85% of lung cancers are classified as nonsmall cell lung cancer (NSCLC). These malignancies can proliferate indefinitely, in part due to dysregulation of the cell cycle and the resulting abnormal cell growth. The specific activation of cyclin-dependent kinases 4 and 6 (CDK4/6) is closely linked to tumour proliferation. Approximately 80% of human tumours exhibit abnormalities in the cyclin D-CDK4/6-INK4-RB pathway. Specifically, CDK4/6 inhibitors either as monotherapy or combination therapy have been investigated in pre-clinical and clinical studies for the treatment of NSCLC, and promising results have been achieved. This review article focuses on research regarding the use of CDK4/6 inhibitors in NSCLC, including the characteristics and mechanisms of action of approved drugs and progress of pre-clinical and clinical research.

Topics

No keywords indexed for this article. Browse by subject →

References

138

[1]

10.3322/caac.21338

[2]

Lung cancer

Alesha A Thai, Benjamin J Solomon, Lecia V Sequist et al.

The Lancet 10.1016/s0140-6736(21)00312-3

[3]

10.1016/j.jtho.2016.05.021

[4]

Romaszko "Multiple primary lung cancer: a literature review" Adv Clin Exp Med (2018) 10.17219/acem/68631

[5]

Qin "[Research progress of CDK4/6 inhibitors in non-small cell lung cancer]" Zhongguo Fei Ai Za Zhi (2020)

[6]

Qi "[PI3K/Akt/mTOR signaling pathway and non-small cell lung cancer]" Zhongguo Fei Ai Za Zhi (2010)

[7]

10.1016/j.jtho.2021.11.003

[8]

Bai "The accomplices of NF-κB lead to radioresistance" Curr Protein Pept Sci (2015) 10.2174/138920371604150429152328

[9]

10.18632/oncotarget.9670

[10]

Receptor signaling as a regulatory mechanism of DNA repair

Raymond E. Meyn, Anapama Munshi, John V. Haymach et al.

Radiotherapy and Oncology 10.1016/j.radonc.2009.06.031

[11]

Liu "Drug resistance to targeted therapeutic strategies in non-small cell lung cancer" Pharmacol Ther (2020) 10.1016/j.pharmthera.2019.107438

[12]

Suresh "Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities" Chest (2018) 10.1016/j.chest.2018.08.1048

[13]

10.1016/j.tcb.2018.07.002

[14]

Sandhu "Deregulation of the cell cycle in cancer" Cancer Detect Prev (2000)

[15]

Malumbres "Cell cycle deregulation: a common motif in cancer" Prog Cell Cycle Res (2003)

[16]

Tavakolian "Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers" Infect Agent Cancer (2020) 10.1186/s13027-020-00295-7

[17]

Qin "Cyclin-dependent kinase inhibitors for the treatment of lung cancer" Expert Opin Pharmacother (2020) 10.1080/14656566.2020.1738385

[18]

Cell cycle proteins as promising targets in cancer therapy

Tobias Otto, Piotr Sicinski

Nature Reviews Cancer 10.1038/nrc.2016.138

[19]

"Milestones in cell division" Nat Cell Biol (2001) 10.1038/ncb1201-e265

[20]

10.1007/s10549-017-4612-y

[21]

Bonelli "Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immunomodulation" Biochem Pharmacol (2019) 10.1016/j.bcp.2019.113676

[22]

10.1158/1078-0432.ccr-14-0816

[23]

10.1016/j.ctrv.2016.03.002

[24]

10.1158/1535-7163.mct-19-0162

[25]

10.1158/2159-8290.cd-15-0894

[26]

10.1158/2159-8290.cd-nb2017-112

[27]

Murphy "The role of CDK4/6 inhibitors in breast cancer" Curr Treat Options Oncol (2019) 10.1007/s11864-019-0651-4

[28]

Corona "CDK4/6 inhibitors in HER2-positive breast cancer" Crit Rev Oncol Hematol (2017) 10.1016/j.critrevonc.2017.02.022

[29]

Bilgin "A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer" Curr Med Res Opin (2017) 10.1080/03007995.2017.1348344

[30]

Syed "Ribociclib: first global approval" Drugs (2017) 10.1007/s40265-017-0742-0

[31]

10.3390/ijms21186479

[32]

10.1186/s13058-021-01409-8

[33]

10.1007/s10549-020-05755-7

[34]

10.1007/s10549-018-05125-4

[35]

10.3389/fonc.2018.00608

[36]

10.1038/nature25015

[37]

10.1038/nature23465

[38]

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Mattia Garutti, Giada Targato, Silvia Buriolla et al.

Cells 2021 10.3390/cells10061334

[39]

Tempka "Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair" Redox Biol (2018) 10.1016/j.redox.2017.12.017

[40]

10.1016/j.phrs.2020.104686

[41]

Zhang "Mechanisms and implications of CDK4/6 inhibitors for the treatment of NSCLC" Front Oncol (2021) 10.3389/fonc.2021.676041

[42]

10.1158/1078-0432.ccr-17-2074

[43]

10.1200/jco.2016.69.0032

[44]

Treating cancer with selective CDK4/6 inhibitors

Ben O'Leary, Richard S. Finn, Nicholas C. Turner

Nature Reviews Clinical Oncology 10.1038/nrclinonc.2016.26

[45]

10.1158/0008-5472.can-05-2203

[46]

10.1242/jcs.039131

[47]

10.1016/j.cub.2006.04.044

[48]

Lin "Targeting cyclin-dependent kinases for treatment of gynecologic cancers" Front Oncol (2018) 10.3389/fonc.2018.00303

[49]

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

D. Williams Parsons, Siân Jones, Xiaosong Zhang et al.

Science 10.1126/science.1164382

[50]

10.1158/2159-8290.cd-17-0915

Showing 50 of 138 references

Metrics

26

Citations

138

References

Details

Published: Jan 31, 2024
Vol/Issue: 33(171)
Pages: 230145
License: View

Authors

Shanghai Dianji University

Cite This Article

Shuoshuo Lv, Jie Yang, Jiayuh Lin, et al. (2024). CDK4/6 inhibitors in lung cancer: current practice and future directions. European Respiratory Review, 33(171), 230145. https://doi.org/10.1183/16000617.0145-2023

CDK4/6 inhibitors in lung cancer: current practice and future directions

You May Also Like